- Home
- NA vs ELUT Comparison
NA vs ELUT Comparison
Compare NA & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- ELUT
- Stock Information
- Founded
- NA 2019
- ELUT 2015
- Country
- NA China
- ELUT United States
- Employees
- NA N/A
- ELUT N/A
- Industry
- NA Semiconductors
- ELUT Medical Specialities
- Sector
- NA Technology
- ELUT Health Care
- Exchange
- NA Nasdaq
- ELUT Nasdaq
- Market Cap
- NA 77.6M
- ELUT 73.2M
- IPO Year
- NA 2022
- ELUT 2020
- Fundamental
- Price
- NA $12.17
- ELUT $1.81
- Analyst Decision
- NA
- ELUT Strong Buy
- Analyst Count
- NA 0
- ELUT 2
- Target Price
- NA N/A
- ELUT $8.00
- AVG Volume (30 Days)
- NA 390.5K
- ELUT 25.1K
- Earning Date
- NA 03-25-2025
- ELUT 08-06-2025
- Dividend Yield
- NA N/A
- ELUT N/A
- EPS Growth
- NA N/A
- ELUT N/A
- EPS
- NA N/A
- ELUT N/A
- Revenue
- NA $5,561,770.00
- ELUT $23,711,000.00
- Revenue This Year
- NA N/A
- ELUT $20.10
- Revenue Next Year
- NA N/A
- ELUT $85.89
- P/E Ratio
- NA N/A
- ELUT N/A
- Revenue Growth
- NA N/A
- ELUT N/A
- 52 Week Low
- NA $2.75
- ELUT $1.61
- 52 Week High
- NA $13.86
- ELUT $5.24
- Technical
- Relative Strength Index (RSI)
- NA 76.74
- ELUT 45.88
- Support Level
- NA $7.75
- ELUT $1.72
- Resistance Level
- NA $12.94
- ELUT $1.96
- Average True Range (ATR)
- NA 1.91
- ELUT 0.15
- MACD
- NA 0.44
- ELUT 0.01
- Stochastic Oscillator
- NA 88.48
- ELUT 24.13
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.